191 related articles for article (PubMed ID: 34161649)
1. Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study.
Viitala A; Anttinen M; Wright C; Virtanen I; Mäkelä P; Hovinen T; Sainio T; Saunavaara J; Taimen P; Blanco Sequeiros R; Boström PJ
BJU Int; 2022 Feb; 129(2):208-216. PubMed ID: 34161649
[TBL] [Abstract][Full Text] [Related]
2. Relief of Lower Urinary Tract Symptoms After MRI-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: Subgroup Analyses in Patients with Concurrent Cancer and Benign Prostatic Hyperplasia.
Elterman D; Li W; Hatiboglu G; Relle J; Zorn KC; Bhojani N; Chin J
J Endourol; 2021 Apr; 35(4):497-505. PubMed ID: 32935575
[No Abstract] [Full Text] [Related]
3. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
[TBL] [Abstract][Full Text] [Related]
4. Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA).
Lumiani A; Samun D; Sroka R; Muschter R
Urol Oncol; 2021 Dec; 39(12):830.e9-830.e16. PubMed ID: 34144892
[TBL] [Abstract][Full Text] [Related]
5. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience.
Gilling P; Reuther R; Kahokehr A; Fraundorfer M
BJU Int; 2016 Jun; 117(6):923-9. PubMed ID: 26477826
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy using a low-powered holmium laser for enucleation of the prostate (HoLEP): 12-month results from a prospective low-power HoLEP series.
Becker B; Gross AJ; Netsch C
World J Urol; 2018 Mar; 36(3):441-447. PubMed ID: 29275506
[TBL] [Abstract][Full Text] [Related]
7. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study.
Kadner G; Valerio M; Giannakis I; Manit A; Lumen N; Ho BSH; Alonso S; Schulman C; Barber N; Amparore D; Porpiglia F
World J Urol; 2020 Dec; 38(12):3235-3244. PubMed ID: 32124019
[TBL] [Abstract][Full Text] [Related]
8. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.
Porpiglia F; Fiori C; Amparore D; Kadner G; Manit A; Valerio M; Nicolaas L; Ho BSH; Alonso S; Schulman C; Barber N
BJU Int; 2019 Jun; 123(6):1061-1069. PubMed ID: 30382600
[TBL] [Abstract][Full Text] [Related]
9. Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results.
Anttinen M; Mäkelä P; Viitala A; Nurminen P; Suomi V; Sainio T; Saunavaara J; Taimen P; Sequeiros RB; Boström PJ
Eur Urol Open Sci; 2020 Dec; 22():79-87. PubMed ID: 34337481
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters.
Hatiboglu G; Popeneciu V; Bonekamp D; Burtnyk M; Staruch R; Pahernik S; Tosev G; Radtke JP; Motsch J; Schlemmer HP; Hohenfellner M; Nyarangi-Dix JN
World J Urol; 2020 Feb; 38(2):343-350. PubMed ID: 31062122
[TBL] [Abstract][Full Text] [Related]
11. Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results.
Bhojani N; Bidair M; Kramolowsky E; Desai M; Doumanian L; Zorn KC; Elterman D; Kaufman RP; Eure G; Badlani G; Plante M; Uchio E; Gin G; Paterson R; So A; Roehrborn C; Motola J; Kaplan S; Humphreys M
J Urol; 2023 Jul; 210(1):143-153. PubMed ID: 37115632
[TBL] [Abstract][Full Text] [Related]
12. Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial.
Abt D; Müllhaupt G; Hechelhammer L; Markart S; Güsewell S; Schmid HP; Mordasini L; Engeler DS
Eur Urol; 2021 Jul; 80(1):34-42. PubMed ID: 33612376
[TBL] [Abstract][Full Text] [Related]
13. Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
McVary KT; Gange SN; Gittelman MC; Goldberg KA; Patel K; Shore ND; Levin RM; Rousseau M; Beahrs JR; Kaminetsky J; Cowan BE; Cantrill CH; Mynderse LA; Ulchaker JC; Larson TR; Dixon CM; Roehrborn CG
J Urol; 2016 May; 195(5):1529-1538. PubMed ID: 26614889
[TBL] [Abstract][Full Text] [Related]
14. "In-bore" MRI prostate biopsy is a safe preoperative clinical tool to exclude significant prostate cancer in symptomatic patients with benign prostatic obstruction before transurethral laser enucleation.
Porreca A; D'Agostino D; Vigo M; Corsi P; Romagnoli D; Del Rosso A; Schiavina R; Brunocilla E; Artibani W; Giampaoli M
Arch Ital Urol Androl; 2020 Jan; 91(4):224-229. PubMed ID: 31937084
[TBL] [Abstract][Full Text] [Related]
15. Ejaculatory function following transperineal laser ablation vs TURP for benign prostatic obstruction: a randomized trial.
Bertolo R; Iacovelli V; Cipriani C; Carilli M; Vittori M; Antonucci M; Maiorino F; Signoretti M; Petta F; Travaglia S; Panei M; Bove P
BJU Int; 2023 Jul; 132(1):100-108. PubMed ID: 36917033
[TBL] [Abstract][Full Text] [Related]
16. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Hwang EC; Jung JH; Borofsky M; Kim MH; Dahm P
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD013143. PubMed ID: 30759311
[TBL] [Abstract][Full Text] [Related]
17. Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses.
Reale G; Marchioni M; Altieri V; Greco F; De Nunzio C; Destefanis P; Ricciardulli S; Bergamaschi F; Fasolis G; Varvello F; Voce S; Palmieri F; Divan C; Malossini G; Oriti R; Tuccio A; Ruggera L; Tubaro A; Delicato G; Laganà A; Dadone C; De Rienzo G; Ditonno A; Frattini A; Pucci L; Carrino M; Montefiore F; Germani S; Miano R; Schips L; Rabito S; Ferrari G; Cindolo L
Minerva Urol Nefrol; 2020 Oct; 72(5):622-628. PubMed ID: 32284526
[TBL] [Abstract][Full Text] [Related]
18. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results.
Amparore D; De Cillis S; Schulman C; Kadner G; Fiori C; Porpiglia F
Minerva Urol Nephrol; 2023 Dec; 75(6):743-751. PubMed ID: 37350585
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study.
Nair SM; Hatiboglu G; Relle J; Hetou K; Hafron J; Harle C; Kassam Z; Staruch R; Burtnyk M; Bonekamp D; Schlemmer HP; Roethke MC; Mueller-Wolf M; Pahernik S; Chin JL
BJU Int; 2021 May; 127(5):544-552. PubMed ID: 33037765
[TBL] [Abstract][Full Text] [Related]
20. First-in-man Safety and Efficacy of the ClearRing Implant for the Treatment of Benign Prostatic Hyperplasia.
Vjaters E; Nitsan D; Mullerad M; Engelstein D; Leibovitch I; Feld Y
Eur Urol Focus; 2020 Jan; 6(1):131-136. PubMed ID: 30293945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
